Background: Intravenous iron (IV iron) and Erythropoiesis-Stimulating Agents (ESAs)
INTRODUCTION
Anemia develops in most patients with end-stage renal disease treated by HD [1] although appropriate management is still challenging [2] ; important and severe anemia is correlated with increased morbidity and mortality [3] [4] [5] [6] .Concomitantly correcting anemia may ameliorate ventricular hypertrophy [7] [8] [9] , reduce mortality and the risks of hospitalization [10, 11] and improve the quality of life [12, 13] .
Optimal medical strategy for management of anemia is a fine balance between Erythropoiesis-Stimulating Agents (ESAs) and Intravenous (IV) iron. Initial guidelines targeted Hb>11 g/dL [14] which often necessitated increased ESAs administration. However randomized trials comparing Hb targets on mortality and vascular events [7, 15] showed unexpectedly that higher Hb targets appeared to increase the risk of death [16] and major cardiovascular events [17] raising the possibility that the association may be secondary to higher ESAs doses [17] . ESAs doses in HD patients in the United States [18, 19] and in Europe [20] have decreased since the addition of a black box warning to the labeling and the introduction of a bundled payment methodology in 2011 in United States [21, 22] and in 2013 in France [23] .
Administration of IV iron complements ESA therapy, helps to maintain target Hb levels, and lowers ESA requirements [24] .
Recently, the use of IV iron has increased and is likely related to reductions in ESA use [25] . However IV iron use also requires a careful balance between intended clinical effects and uncertain risks of toxicities [26] and concerns have been raised regarding the potential for IV iron to cause oxidative stress, inflammation, endothelial dysfunction and immune dysfunction as such prompting calls for caution regarding the potential hazards of high exposure to IV iron [27] [28] [29] .
Recent studies suggest adverse outcomes from cumulative exposure to either IV iron [30] [31] [32] [33] [34] [35] [36] [37] or ESA [38] [39] [40] [41] [42] [43] [44] although they do not assess the combination of both IV iron and ESA (and differing doses) in HD patients as reflects routine clinical practice. Nevertheless some studies suggest that higher doses IV iron is not associated with higher risk of mortality, infection, cardiovascular events, or hospitalizations in adult patients on dialysis [45] .
This retrospective observational study aimed to investigate the impact of combined and total anemia therapy using ESAs and IV iron on all-cause mortality and hospitalization in a cohort of incident HD patients over more than nine years in a single unit.
MATERIAL AND METHODS

Study Design
Retrospective observational single-center study of incident patients undergoing HD in France with data collected between January 2004 and December 2012. Previous period (predialysis period) could not be analyzed.
All patients during this period were included except those that had less than 90 days of retrievable data. Signed consent authorizing the use of their clinical data for research was obtained from all participants, although Ethics Committee approval is not required per French regulations.
Data Collection
Data was extracted from the Hemodial ® database. This database was largely used for different publications [46, 47] .
Demographic and outcome variables collected included gender, age, body mass index, primary renal disease, Charlson Co-morbidity Index (CCI), ethnic origin and morbidity / end of study events (death, transplantation, transfer to other unit) and/or hospitalization including causes and duration.
Laboratory data included hemoglobin (Hb), ferritin, transferrin saturation (TSAT), CRP and albumin.
Patient Management
All patients included were undergoing HD sessions; these included 95% of high flux dialyzers, 92% of native arteriovenous fistulas, 5% grafts and 3% of permanent central venous catheters, ultrapure dialysate without aluminum and chloramines, and a target Kt/V> 1.4. Regular HD session duration was 4 hours three times a week for 95% of the patients.
ESA use was exclusively Darbepoetin Alfa [DA] , during the entire study, injected IV at the end of the dialysis session, once every other week (during the first dialysis session of the week) via the venous injection site before the drip chamber on the venous line [48] . Any change in the DA dosing required a follow-up of four Hb measurements, each performed every two weeks, and the adaptation of the next injected dose was decided by the patient primary physician and decision based on the clinical setting of the dialysis sessions (clotting episodes, hemorrhages, blood losses) and the clinical program of the patient (programmed surgery, specific investigations..); if on the last 4 Hb values, one was outside of the target (11.5-12 g/dL during the entire study) nothing was changed in the DA dosing; if 2 to 3 values were outside of the target, the dosing was adapted depending on the amplitude of the variation.
ESA dose requirement was recorded per patient during the entire attendance of the patient in the unit, and expressed as total dose for each patient (µg), dose per session (µg/dialysis session), ESA dose in µg/Kg/week and Erythropoietin Resistance Index (ERI), calculated by dividing the weekly bodyweight-adjusted DA dose by the Hb concentration.
Intravenous iron was exclusively Iron Sucrose (IS) and injected, when necessary, during the six first years once a week during the second dialysis session of the week at a dose ranging from 25 to 100 mg. After a publication developing the synergistic effect of the administration of IV iron and ESA together [49] during the same dialysis session, IV iron was injected for the last three years, once every two weeks simultaneously with DA during the same dialysis session. IV iron was diluted with saline solution (0.9%) up to 20 ml volume and infused over a one- 
RESULTS
Baseline characteristics
Three hundred and seventy (370) incident HD patients were included in the 9 year observational period. The majority (69%) were male and the mean age (SD) at initiation of HD was 55. 
Patient Status and Overall Outcomes
At the end of the observational period, 132 pts (35.6%) were still on dialysis and the others had achieved outcomes of kidney transplantation (108 patients; 29.1%), were transferred to another unit (39 patients; 10.3%) or died (89 patients; 24%). The deaths were mainly due to cardiovascular diseases (43.8%), malignancy (15.7%), infection (12.2%) and other reasons (various or unknown origin: 28.3%). The total survival curves are 88% survival at 1000 days (2.7 years), 57% at 2000 days (5.5 years) and 24% at 3000 days (8.2 years).
Overall, 218 (59%) patients had a total of 554 hospitalizations for a total duration of 5511 days (less than 0.2% of the 300,000 days of study period). The reasons for hospitalization were primarily due to cardiovascular disease (25%), infection non-related to vascular access (23%), vascular access related events (21%) and malignancy (15%). Figure 1A ; IV iron adjusted model: HR=2.10; 95% CI 1.13-2.35, Figure 1B ).
The boxes combining ESA and IV iron on survival
Patients were divided into 9 cohorts based on ESA and IV iron dosing and the number of patients (around 50 per group), gender, mean age at start, primary renal disease, Charlson comorbidity index or BMI were all similar (Table 4) . When the nine groups were analyzed for survival (Table 5) Table 2 : Main mean laboratory data of the study. Table 3 : Main parameters about ESA and IV iron during the study (n=370). (Table 7) , where the ESA impact was twice as strong as the impact of iron. Age, gender, BMI,
Charlson index, ferritin and hospitalization appeared to have no effect. Hb indicates a better survival when the level is between 11 and 12 g/dL.
Overall survival (at 3000 days) was significantly better in the group with low doses (DA <8.5µg and IS <15mg iron per session: 70% survival) compared with the group having midrange doses (DA 8.6-14 µg and IS 15.1-25mg iron per session: 57% survival; p<0.002) and was worst in the group having high doses of both treatments (0%; p<0.0001). At 1000 days, survival is near identical in combined low and mid-dosing cohorts (100% and 96% respectively) but higher than for the cohort with high doses of both ESA and IV iron (67%).
The improved survival of combined low or mid-dosing groups compared to ESA and IV high groups appeared to be related to age at initiation of HD, Hb concentration (at time of commencing HD) and mean Hb level during the first year of HD [11.7(0.7),compared to 10.8 (0.9), p<0.007]. Additionally, serum ferritin and TSAT were higher at start and during the first year of dialysis supporting the possibility that these patients were previously (during the pre-dialysis period) appropriately iron replete. As expected, ESA dose and IV iron dose are lower in the first two groups compared to the third group however the ESA dose progressively declined in low and mid-dosing groups during the first year (average decrease of 36%) whilst remained effectively stable (decrease of 6%) for the high-dose group (Table 8) . Analyzing the mortality (Table   9 ), death and specifically cardiovascular mortality is increasing with the ESA dose (p< 0.05), while they remain stable when the Iron doses are increasing.
Discussion
This study assesses the impact on survival of dosing with both ESA and IV iron during dialysis in HD patients. When assessing either product alone, high doses of ESA (>13µg/session) or high doses of IV iron (>25mg/session) suggest a risk for higher mortality. However, when stratifying the groups by ESA and IV iron doses (low, mid or high dosing), the impact of increasing IV iron (when maintaining low ESA doses) appeared to have little / no impact on mortality whilst increasing ESA dose (especially above 8.5µg per session) resulted in increased mortality at 2000 and 3000 days (and the impact was magnified if the dose of IV iron was also increased). The multivariate analysis suggests that the ESA impact on survival is twice as important when compared to IV iron. (26) 11 (22) 9 (18) 4 (18) 14 (35) 7 (18) 10 (25) 5 (12) 4 (10) 6 (20) 10 (34) 4 (14) 5 (16) 6 (20) 13 (34) 12 (30) 4 (10) 9 (23) 1 (3) 14 (28) 11 (23) 11 23) 11 (23) 2 (3) 12 (29) 12 (29) 6 (15) 9 (22) 2 (5) 8 (22) 9 (25) 13 (36) 5 (14) 1 (3) 7 (22) 5 (16) 8 (26) 10 (32) 2 (2) 13 (24) 16 (28) 16 (28) (53) 2 (7) 1 (4) 15 (38) 9 (23) 11 (28) 4 (11) 14 (29) 13 (26) 18 (37) 4 (8) 15 (37) 14 (34) 7 (17) 5 (12) 21 (58) 5 (14) 8 (22) 2 (6) 7 (22) 9 (29) 12 (37) 4 (12) 15 (28) 8 (15) 25 (47) The increased risk for either single product is reflected in the literature with numerous studies suggesting adverse outcomes from cumulative exposure to either IV iron [30] [31] [32] [33] [34] [35] [36] [37] or ESA's [38] [39] [40] [41] [42] [43] [44] . Whilst our data support these findings (when looking at either product alone, Figure 1 ) our data also suggest that it is more important to assess both ESA and IV iron dosing together to understand the relative negative impact of the combined therapy (and then the individual products within the combination). The same approach was evocated by Ellis and
Brookhart [51] in a setting with two concurrent treatments: IV iron treated concurrently with ESA in hemodialysis patients.
That said, a recently reported abstract [52] , conducted in a similar manner to our study, on 1086 patients but a short period of three years, concluded that high doses of ESA and iron are significantly associated with higher risks of cardiovascular disease and death. But regarding the combined effect of both ESA and IV iron, their conclusions are the opposite of our: regardless of ESA dose a higher dose of iron is significantly associated with a higher risk. This differs from our finding and warrants further (ideally prospectively controlled studies) to further elucidate the best management strategies. In relation to ESA, many questions have been raised since the Food and Drugs Administration revised the prescribing instructions for ESA [21, 53] : toxicity of ESA, dose and consequences of hyporesponsiveness, ERI, hemoglobin target (which was stable all over the study), increased risk of cardiovascular related mortality. Alone, ESA does not appear to be a toxic drug, however there are no randomized studies to prove/disprove this. Various mathematical approaches appear in the literature: Perez-Garcia et al uses a propensity score matching for each patient by modeling the probability of receiving > or 8000 IU/week using logistic regression model [44] : in his model the fifth quintile (>8127 IU/week) is an independent predictor of mortality. Streja et al using a marginal structural model defines that there is a dose- Table 5 : Main characteristics of each of the nine groups identified. A second parameter that may predict mortality of patients receiving ESA is (hypo) responsiveness. They are multiple causes of hyporesponsiveness including iron deficiency, noncontrolled hyperparathyroidism, central venous catheters and its blood losses [57] , aluminum toxicity, malnutrition, and some other drugs. Some authors state that ESA responsiveness, rather than dose, is the major determinant of adverse events in HD pts [41, [58] [59] [60] .If the patient has malnutrition, it may be beneficial to try to improve the nutritional status (at least increase the albumin level) of those in malnutrition to avoid more dose of ESA and iron administration [61] Is Erythropoietin
Resistance Index (ERI) a good indicator for the degree of responsiveness to ESAs ?; ERI is related to mortality even in our study with a cut off at 10 UI/kg/week/g Hb with a survival of 87% at 5 years when ERI is under 10, and of 48% at 5 years when ERI is over 10 (p<0.00001). However this index has some limitations: by the definition ERI is strongly related to ESA dose and weight [62] . When the ESA dose is changed, ERI is also modified without information about the mechanism of resistance. If the Hb level increased, independently of the ESA administration, ERI is also impacted. Chait et al conclude that ERI is not an adequate independent measure of ESA resistance [62] , when Okazaki et al suggest that ERI is a good index [63] .
The notion of a well and on a long-term Hb level in HD patients is controversial. In our study, the target Hb level remains identical over the nine year period, and is stable since 1999.
Low concentration of Hb is associated with an increased mortality risk [64] . The intended Hb target influences the ESA dose. In many units the target changes with years [65, 66] The administration of ESA's could increase the risk of cardiovascular-related mortality. Some events have been correlated to high ESA dose: hypertension, stroke and thrombotic events [16, 56, 67] . High-dose ESA-treated patients with higher target Hb levels, and poorly controlled hypertension, manifest a high risk of mortality, with a direct ESA effect proposed to be causal [14] . A similar association between ESA dose and an increased risk of stroke has been described, particularly in patients with poorly controlled hypertension, or those with a prior history of stroke [56] . In our study there was a tendency of higher cardio vascular mortality as the ESA dose is increasing, while it was not the case with IV Iron. 69 (70) 31 (30) 39 (75) 13 ( The type of ESAs could not be analyzed in our study, as Darbepoetin alfa was all over the study the single ESA used in our unit [68] . In a recent study Sakaguchi et al compared mortality risk of users of short-acting ESAs with those of longacting ESAs (like Darbepoeitin) [69] . Using Cox proportional hazards models the authors found that the relative risk of death was 13% higher among long-acting ESA users compared with short-acting ESA users. The use of IV iron was not studied and our survival at two years ( Figure 1 ) is much better in any case that in the Japanese study [69] . The same difference in survival was estimated by Wilhelm-Leen et al [70] and observed without any significance by Winkelmayer et al [71] .
Optimal treatments for anemia (in 2018) include ESA and iron therapy, with the later mostly comprised of IV iron [73, 73] . Our study underlines this fact in that only four pts out of the 370 did not receive a single dose of IV iron (two of them in relation with hypersensitivity during the pre-dialysis period, and two of them for genetic hemochromatosis Cardiovascular disease is the leading cause of death among HD pts and there are theoretical concerns that IV iron may increase the risk of CV-related outcomes through inducing increased oxidative stress [28, 76] . IV iron has generally not been shown to increase the risks for infection-related mortality. The present study has several strengths and limitations: the prospective recruitment of all patients starting dialysis treatment over a nine years period, with various ethnic origin, However, it is a single center observational study with only 370 patients and lacked control groups that were not treated with IV iron or ESA (and groups were not stratified or randomized in any manner).
In conclusion, patients receiving doses <8. 
